Dr. Conway et al reply

We thank Sauret et al¹ for their interest in our systematic literature review that explored potential diagnostic confusion between giant cell arteritis (GCA) and the coronavirus disease 2019 (COVID-19). This was a particularly important consideration during the early months of the COVID-19 pandemic, when community testing for SARS-CoV-2 was limited and diagnostic tests for GCA were restricted or unavailable due to redeployment of staff.²

The case reported by Sauret et al¹ should be interpreted with caution. GCA is a multifactorial autoimmune disease; infections and vaccines are possible triggers, but a direct causal relationship has never been demonstrated. *HLA-DRB1*04* allele carriage is common in Northern European populations; as well as being one of the genetic factors associated with GCA³ and rheumatoid arthritis, *HLA-DRB1*04* carriage has also been linked with immunosenescence and “inflamm-aging.”^{4,5}

Notwithstanding the temporal association described by Sauret et al,¹ causal links cannot be established from isolated cases. Assuming a conservative incidence of 7 cases per 100,000 people and a population of 26 million people over the age of 50 years in a Northern European country, one would expect approximately 1820 cases per year of GCA. Assuming a random incidence within the year and absence of causal association with COVID-19 vaccination, over 100 cases would be expected within 2 weeks of COVID-19 vaccination (Table 1). Large, population-based studies, ideally with the dates of both GCA symptom onset and GCA diagnosis, might help to determine whether the incidence of diagnosed GCA is genuinely increased during periods of mass COVID-19 vaccination, or whether patients are simply more likely to present promptly to medical care if they develop symptoms after a new vaccine (detection bias).

People—both patients and physicians—may be inclined to make sense of illnesses by making links to other elements of the

medical history. In a community-based UK study of 654 patients with polymyalgia rheumatica,⁶ many respondents related their condition to a prior event, including personal stress, injury, infection, statins, various treatments or surgeries, insect bites, weather conditions, unaccustomed exercise, and (occasionally) influenza vaccination. However, well-designed epidemiological studies are necessary to determine whether such relationships truly exist in the population. Given the limitations associated with uncontrolled observational case reports, and the inevitability that, by chance alone, some patients will be diagnosed with new diseases after a vaccine, we must be cautious in the reporting and interpretation of cases such as this.¹ Caution is especially relevant at times like these when we see variations in population vaccine uptake. Stories have power, and we must be careful to use that power wisely.

Richard Conway¹ , PhD
Elisabeth Brouwer² , PhD
Kornelis S.M. van der Geest² , PhD
Sarah L. Mackie³ , PhD
Puja Mehta⁴ , MBBS
Michael Putman⁵ , MD
Philip Robinson⁶ , PhD
Sebastian Sattui⁷ , MD, MS

¹Department of Rheumatology, St James's Hospital, Dublin, Ireland;

²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;

³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, UK;

⁴Centre for Inflammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, and Department of Rheumatology, University College London

Table 1. Estimates of the number of new cases per year of various rheumatic diseases that might be expected, by chance, to present within 2 weeks of receiving a COVID-19 vaccine.

Rheumatic Disease	Annual Incidence per Population Denominator	New Cases/Year in France ^a	New Cases/Year in France Occurring by Chance Within 2 Weeks of COVID-19 Vaccine ^b
Giant cell arteritis	7–10 per 100,000 ^{c,d}	1820–2600	140–200
Polymyalgia rheumatica	94.9–96.8 per 100,000 ^{c,f}	31,317–31,944	2409–2457
Rheumatoid arthritis	8.8 per 100,000 ^g	5896	454
Systemic lupus erythematosus	3.32 per 100,000 ^h	2224	171
ANCA-associated vasculitis	23.1 per 1,000,000 ⁱ	1548	119

^a Assumes the following population in France: 67 million (total); 26 million (aged > 50 yrs); 33 million (aged > 40 yrs); and 51 million (aged > 20 yrs). ^b Assumes a 2-dose annual vaccine and 100% vaccination rate. ^c Aged > 50 yrs. ^d Mahr et al⁷ (2020). ^e Aged ≥ 40 yrs. ^f Partington et al⁸ (2018). ^g Guillemin et al⁹ (1994). ^h Arnaud et al¹⁰ (2014). ⁱ Pearce et al¹¹ (2016). ANCA: antineutrophil cytoplasmic antibody; COVID-19: coronavirus disease 2019.

Hospital (UCLH) NHS Trust, London, UK;
⁵Medical College of Wisconsin, Milwaukee, Wisconsin, USA;
⁶University of Queensland Faculty of Medicine, Brisbane, Australia;
⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

The authors declare no conflicts of interest relevant to this article.

Address correspondence to Dr. S.L. Mackie, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds LS7 4SA, UK. Email: s.l.mackie@leeds.ac.uk.

REFERENCES

1. Sauret A, Stievenart J, Smets P, et al. Case of giant cell arteritis after SARS-CoV-2 vaccination: a particular phenotype? *J Rheumatol* 2022;49:120.
2. Mackie SL, Brouwer E, Conway R, et al. Clinical pathways for patients with giant cell arteritis during the Covid-19 pandemic: an international perspective. *Lancet Rheumatol* 2021;3:e71-82.
3. Mackie SL, Taylor JC, Haroon-Rashid L, et al; UK GCA Consortium; UKRAG Consortium. Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. *Arthritis Res Ther* 2015;17:195.
4. Schönland SO, Lopez C, Widmann T, et al. Premature telomeric loss in rheumatoid arthritis is genetically determined and involves both myeloid and lymphoid cell lineages. *Proc Natl Acad Sci U S A* 2003;100:13471-6.
5. Thewissen M, Somers V, Venken K, et al. Analyses of immunosenescent markers in patients with autoimmune disease. *Clin Immunol* 2007;123:209-18.
6. Tshimologo M, Saunders B, Muller S, Mallen CD, Hider SL. Patients' views on the causes of their polymyalgia rheumatica: a content analysis of data from the PMR cohort study. *BMJ Open* 2017;7:e014301.
7. Mahr A, Belhassen M, Paccalin M, Devauchelle-Pensec V, Nolin M, Gandon S, et al. Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data. *Rheumatology* 2020;59:120-8.
8. Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul Sultan A. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. *Ann Rheum Dis* 2018;77:1750-6.
9. Guillemain F, Briançon S, Klein JM, Sauleau E, Pourel J. Low incidence of rheumatoid arthritis in France. *Scand J Rheumatol* 1994;23:264-8.
10. Arnaud L, Fagot JP, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. *Autoimmun Rev* 2014;13:1082-9.
11. Pearce FA, Lanyon PC, Grainge MJ, et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. *Rheumatology* 2016;55:1656-63.